GlassScriptPhysician profile
Bailee Elizabeth Pope
NPI 1033834411
$2,134.46
in general payments reported to CMS, 2019-2025
37 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $1,479 · 2024: $319 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.24 |
| Education | $190.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $269.93 | 2022-2023 | Darzalex, Imbruvica, Erleada |
| Gilead Sciences, INC. | $157.02 | 2023-2025 | Trodelvy |
| Seagen INC. | $149.63 | 2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $146.28 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $131.91 | 2023 | Xpovio |
| Incyte Corporation | $121.23 | 2022-2023 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $93.24 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $92.32 | 2022-2024 | Lynparza |
| Beigene USA, INC. | $86.23 | 2023 | Brukinsa |
| Celgene Corporation | $83.66 | 2023-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $75.85 | 2024 | |
| Abbvie INC. | $72.78 | 2022-2024 | |
| Stemline Therapeutics INC. | $67.04 | 2023-2024 | Orserdu |
| Mirati Therapeutics, INC. | $60.91 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $48.04 | 2022-2023 | Tazverik |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailee Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.